Biotech News

Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium

Nautilus Biotechnology (NAUT)Nautilus BiotechnologyCompany update

Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics

Related news

Nautilus Biotechnology

Single-Molecule Proteomics Platform Nautilus Biotechnology is a development-stage life sciences company building a single-molecule proteomics platform intended to make comprehensive protein analysis more accessible. The platform is designed to quantify proteins and their proteoforms at scale, supporting research in disease biology,...

Recent company news

Stock data

Close
2.17 USD
Market cap
340.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States